Pharmaceuticals News and Research

RSS

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Cipher Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults.

10 May 2010

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

Drug study results, interpretation favour wishes of sponsor pharmaceutical companies

Drug studies financed by pharmaceutical companies frequently show positive results in favour of the sponsor. In the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107(16): 279-85), a research group headed by the Chairman of the Drug Commission of the German Medical Association, Prof. Wolf-Dieter Ludwig, describes the influence of sponsoring on the results, protocol and quality of drugs studies.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

Watson Pharmaceuticals reaches patent litigation settlement with Teva Women's Health

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

10 May 2010

MIT, South Africa announce plans to join patent pool for 'neglected diseases'

Massachusetts Institute of Technology (MIT) and South Africa's Technology Innovation Agency (TIA) will join the Pool for Open Innovation against Neglected Tropical Diseases, Science|Business reports.

10 May 2010

Swedish scientists discover a new method to develop effective antimalarial drugs

Amodiaquine was introduced as an antimalarial drug, but was withdrawn when serious adverse effects were observed. Scientists at the University of Gothenburg, Sweden, have now developed a method that can be used to develop safer drugs.

10 May 2010

PCMA releases statement on PBM Audit Reform and Transparency Act of 2010

Pharmacy benefit managers (PBMs) have pioneered tools - including incentivizing the use of generic medications, e-prescribing, and mail-service pharmacies - that improve savings, access, and safety for consumers and payers. Since the key to access is affordability, payers and policymakers alike should explore broader use of PBMs' cost-savings tools and reject approaches that make prescription drugs more expensive.

7 May 2010

Physicians saying no more often to drug reps

A report out Thursday on the accessibility of doctors to pharmaceutical reps showed that fewer physicians are letting reps visit them. "The number of physicians who were 'rep-accessible,' defined as meeting with at least 70% of salespeople who come calling, dropped by 18% from last year, according to sales and marketing consultants ZS Associates."

7 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010.

7 May 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

7 May 2010